Sept. 8, 2025 — The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for Microbot Medical's Liberty System, the first FDA cleared single-use, remotely operated robotic system for peripheral endovascular procedures. The FDA clearance positions the company to commercialize Liberty in the U.S., with the goal of transforming the field to enable accessibility to advanced robotics without the traditional constraints of capital equipment and a dedicated infrastructure.

Sept. 16, 2025 — PaceMate has appointed Sean Shoffstall as Head of AI, Innovation and Data Strategy. Shoffstall joins PaceMate after holding senior roles with Beginly Health, Welby Health and Auditdata, where he played an integral part in the launch of the first HIPAA-compliant AI-generated audiogram analysis tool in the industry.

Sept. 9, 2025 — Amplitude Vascular Systems (AVS), a medical device company focused on safely and effectively treating severely calcified arterial disease, will present 30-day results of its POWER PAD II U.S. pivotal trial for Pulsatile Intravascular Lithotripsy (PIVL) therapy as a Late Breaking Clinical Trial (LBCT) at the Vascular InterVentional Advances (VIVA) meeting in November in Las Vegas.

Sept. 2, 2025 — Although cardiovascular disease is a leading cause of death for women, they remain underrepresented in clinical trials for common heart conditions. These findings, by investigators in the Smidt Heart Institute at Cedars-Sinai, were presented at the 2025 European Society of Cardiology Congress in Madrid.

Sept. 9, 2025 — The American Venous Forum (AVF), International Society on Thrombosis and Haemostasis (ISTH), National Blood Clot Alliance (NBCA), Penumbra, the PERT Consortium and Society for Vascular Medicine (SVM) have come together to form the Get Out the Clot campaign. The groups have announced findings from a new survey assessing the current state of venous thromboembolism (VTE) care (blood clots).